328 related articles for article (PubMed ID: 3139779)
1. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.
Vogelman B; Gudmundsson S; Leggett J; Turnidge J; Ebert S; Craig WA
J Infect Dis; 1988 Oct; 158(4):831-47. PubMed ID: 3139779
[TBL] [Abstract][Full Text] [Related]
2. [Studies of dosing regimens and combination effects of aminoglycosides and beta-lactam in an experimental Pseudomonas aeruginosa infection in mice].
Kikuchi K
Kansenshogaku Zasshi; 1991 Feb; 65(2):216-25. PubMed ID: 2066605
[TBL] [Abstract][Full Text] [Related]
3. Suboptimal aminoglycoside dosing in critically ill patients.
Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
[TBL] [Abstract][Full Text] [Related]
4. The impact of the pre-treatment interval on antimicrobial efficacy in a biological model.
Gerber AU; Greter U; Segessenmann C; Kozak S
J Antimicrob Chemother; 1993 May; 31 Suppl D():29-39. PubMed ID: 8335522
[TBL] [Abstract][Full Text] [Related]
5. Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model.
den Hollander JG; Mouton JW; van Goor MP; Vleggaar FP; Verbrugh HA
Antimicrob Agents Chemother; 1996 Mar; 40(3):784-6. PubMed ID: 8851612
[TBL] [Abstract][Full Text] [Related]
6. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
[TBL] [Abstract][Full Text] [Related]
7. Postantibiotic suppression of bacterial growth.
Bundtzen RW; Gerber AU; Cohn DL; Craig WA
Rev Infect Dis; 1981; 3(1):28-37. PubMed ID: 6784225
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and experimental data on beta-lactam antibiotics in the treatment of patients.
Craig W
Eur J Clin Microbiol; 1984 Dec; 3(6):575-8. PubMed ID: 6441711
[TBL] [Abstract][Full Text] [Related]
9. Decreased bactericidal activity during the period of the postantibiotic effect.
Gudmundsson S; Vogelman B; Craig WA
J Antimicrob Chemother; 1994 Dec; 34(6):921-30. PubMed ID: 7730235
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of netilmicin-ticarcillin and tobramycin-ticarcillin in the treatment of serious systemic infections in elderly patients.
Jansen W; Schwarz A
Clin Ther; 1984; 7(1):112-20. PubMed ID: 6394127
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.
Huang V; Rybak MJ
Antimicrob Agents Chemother; 2005 Jan; 49(1):302-8. PubMed ID: 15616309
[TBL] [Abstract][Full Text] [Related]
12. An in vivo assessment of the tobramycin/ticarcillin interaction in cystic fibrosis patients.
Roberts GW; Nation RL; Jarvinen AO; Martin AJ
Br J Clin Pharmacol; 1993 Oct; 36(4):372-5. PubMed ID: 12959319
[TBL] [Abstract][Full Text] [Related]
13. In vivo postantibiotic effect in a thigh infection in neutropenic mice.
Vogelman B; Gudmundsson S; Turnidge J; Leggett J; Craig WA
J Infect Dis; 1988 Feb; 157(2):287-98. PubMed ID: 3121761
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
[TBL] [Abstract][Full Text] [Related]
15. Once-daily versus pharmacokinetic dosing of aminoglycosides.
Medicus-Bringa M; Ward G; Rice M
Am J Med; 1997 Oct; 103(4):328-30. PubMed ID: 9382126
[No Abstract] [Full Text] [Related]
16. Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface.
Reed MD
Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):17-24. PubMed ID: 19667545
[TBL] [Abstract][Full Text] [Related]
17. Addition of rifampin to ticarcillin-tobramycin combination for the treatment of Pseudomonas aeruginosa infections: assessment in a neutropenic mouse model.
Zuravleff JJ; Chervenick P; Yu VL; Muder RR; Diven WF
J Lab Clin Med; 1984 Jun; 103(6):878-85. PubMed ID: 6427375
[TBL] [Abstract][Full Text] [Related]
18. The postantibiotic effect induced by antimicrobial combinations.
Gudmundsson S; Erlendsdóttir H; Gottfredsson M; Gudmundsson A
Scand J Infect Dis Suppl; 1990; 74():80-93. PubMed ID: 2129068
[TBL] [Abstract][Full Text] [Related]
19. Antibacterial activity of ticarcillin, tobramycin and gentamicin alone and in combination against Pseudomonas aeruginosa in vitro.
Ullmann U
Chemotherapy; 1977; 23(5):314-23. PubMed ID: 409590
[TBL] [Abstract][Full Text] [Related]
20. [In vitro interaction of tazobactam/piperacillin combined with aminoglycosides against Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli AND Staphylococcus aureus].
Yamada H; Takahata M; Minami S
Jpn J Antibiot; 2002 Feb; 55(1):61-6. PubMed ID: 11977921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
